UK markets closed

Theravance Biopharma, Inc. (0TB.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
8.800.00 (0.00%)
At close: 08:04AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 427.93M
Enterprise value 378.36M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.11
Price/book (mrq)2.16
Enterprise value/revenue 7.08
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.36
52-week change 3-12.87%
S&P500 52-week change 326.43%
52-week high 310.60
52-week low 37.60
50-day moving average 38.45
200-day moving average 38.86

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 548.56M
Implied shares outstanding 648.63M
Float 814.38M
% held by insiders 114.51%
% held by institutions 1106.08%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -96.11%
Operating margin (ttm)-35.53%

Management effectiveness

Return on assets (ttm)-6.73%
Return on equity (ttm)-16.86%

Income statement

Revenue (ttm)57.42M
Revenue per share (ttm)1.04
Quarterly revenue growth (yoy)19.90%
Gross profit (ttm)N/A
EBITDA -53.19M
Net income avi to common (ttm)-55.19M
Diluted EPS (ttm)-0.93
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)102.43M
Total cash per share (mrq)2.13
Total debt (mrq)49.16M
Total debt/equity (mrq)23.08%
Current ratio (mrq)5.39
Book value per share (mrq)4.43

Cash flow statement

Operating cash flow (ttm)-27M
Levered free cash flow (ttm)-13.89M